drugset

drugset / Trial / NCT02449343

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

NCT02449343 ↗

Phase 2/3 Unknown 233 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.

Timeline

Start: 2015-05-12
Primary completion: 2017-04
Completion: 2017-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	—	Oral

Indications